Skip to main content

Tedizolid clearance by in vitro continuous renal replacement therapy model


Tedizolid is an oxazolidinone antibiotic approved to treat acute bacterial skin and soft tissue infection and is under investigation for treatment of nosocomial pneumonia, common in critically ill patients with acute kidney injury. There are limited data on tedizolid disposition in continuous renal replacement therapy (CRRT). This study's purpose was to assess continuous hemofiltration (CHF) and continuous hemodialysis (CHD) influence on tedizolid clearance.


Validated, bovine blood-based, in vitro CHF and CHD models were used with six new HF 1400 (polysulfone) and six new Multiflow 150 (AN 69) hemodiafilters. Tedizolid's transmembrane clearances (CLTM) during CHF and CHD were assessed by measuring sieving (SC) and saturation (SA) coefficients at various ultrafiltrate (Quf ) (1, 2, 3 l/ hour) and dialysate flow rates (Qd) (1, 2, 3 and 6 l/hour), using a blood flow rate (Qb) of 200 ml/minute. Tedizolid adsorption was tested in a 1 l recirculating CHF model at Quf of 2 l/hour and Qb of 200 ml/minute over 4 hours. Adsorption (%) was calculated after correcting for the dilution by CHF priming volume. Urea was added as a control in all experiments.


Urea SC and SA were ~1 in all experiments. In CHF, mean tedizolid SC ranged from 0.52 to 0.57 for HF1400 and from 0.50 to 0.54 for M150. CLTM did not differ between filter types for Quf of 1, 2, and 3 l/hour. In CHD, mean tedizolid SA ranged from 0.46 to 0.56 for HF1400 and from 0.38 to 0.44 for M 150. Tedizolid CLTM with the HF1400 was higher than M150 values at Qd of 6 l/hours (P < 0.02). Tedizolid exhibited irreversible adsorption within 10 minutes. See Figure 1.

figure 1

Figure 1


Tedizolid's CLTM is dependent on hemodiafilter type and Qd for CHD and Quf in CHF. At conventional CRRT rates, tedizolid CLTM appears modest relative to total body clearance and is unlikely to require dose adjustments. CRRT adsorption in the clinical setting is likely less than what we observed in this in vitro, continuously recirculating blood model.

Author information

Authors and Affiliations


Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Lewis, S., Switaj, L. & Mueller, B. Tedizolid clearance by in vitro continuous renal replacement therapy model. Crit Care 19 (Suppl 1), P113 (2015).

Download citation

  • Published:

  • DOI:


  • Acute Kidney Injury
  • Continuous Renal Replacement Therapy
  • Soft Tissue Infection
  • Polysulfone
  • Nosocomial Pneumonia